Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from an average of 10 months to 14 months after diagnosis in the last 5 years due to improvements in the standard of care. Radiotherapy has been of key importance to the treatment of these lesions for decades, and the ability to focus the beam and tailor it to the irregular contours of brain tumors and minimize the dose to nearby critical structures with intensity-modulated or image-guided techniques has improved greatly. Temozolomide, an alkylating agent with simple oral administration and a favorable toxicity profile, is used in conjunction with and after radiotherapy. Newer surgical techniques, such as fluorescence-guided resection and neuroendoscopic approaches, have become important in the management of malignant gliomas. Furthermore, new discoveries are being made in basic and translational research, which are likely to improve this situation further in the next 10 years. These include agents that block 1 or more of the disordered tumor proliferation signaling pathways, and that overcome resistance to already existing treatments. Targeted therapies such as antiangiogenic therapy with antivascular endothelial growth factor antibodies (bevacizumab) are finding their way into clinical practice. Large-scale research efforts are ongoing to provide a comprehensive understanding of all the genetic alterations and gene expression changes underlying glioma formation. These have already refined the classification of glioblastoma into 4 distinct molecular entities that may lead to different treatment regimens. The role of cancer stem-like cells is another area of active investigation. There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.
Van Meir
Erwin G
EG
Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA. evanmei@emory.edu
Hadjipanayis
Costas G
CG
Norden
Andrew D
AD
Shu
Hui-Kuo
HK
Wen
Patrick Y
PY
Olson
Jeffrey J
JJ
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D014408:Biomarkers, Tumor; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D004815:Epidermal Growth Factor / Q000187:drug effects; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008967:Molecular Biology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D004815:Epidermal Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor
J Natl Cancer Inst. 2009 Apr 1;101(7):450-1
19318637
J Clin Oncol. 2009 Feb 10;27(5):740-5
19114704
Semin Radiat Oncol. 2005 Jul;15(3):192-201
15983944
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1397-404
12459362
Curr Opin Neurol. 2008 Dec;21(6):728-35
18989120
J Clin Oncol. 2009 Oct 1;27(28):4733-40
19720927
Curr Opin Investig Drugs. 2006 Dec;7(12):1067-76
17209524
PLoS Med. 2008 Jan 22;5(1):e8
18215105
Neurosurgery. 2008 Mar;62(3 Suppl 1):51-5; discussion 55-6
18424967
Nature. 1985 Jan 10-18;313(5998):144-7
2981413
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44
19277712
Lancet Oncol. 2006 May;7(5):392-401
16648043
Oncogene. 2007 Aug 16;26(38):5577-86
17369861
Acta Neurochir Suppl. 2003;88:169-77
14531575
J Exp Med. 1997 Oct 20;186(8):1201-12
9334359
Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69
15094120
Science. 2007 Oct 12;318(5848):287-90
17872411
Clin Cancer Res. 2007 May 1;13(9):2728-37
17473206
J Mol Med (Berl). 2009 Apr;87(4):363-74
19189072
Clin Cancer Res. 2009 May 15;15(10):3617-23
19417015
Cancer Res. 1992 Aug 15;52(16):4297-305
1643627
Cancer Cell. 2010 Jan 19;17(1):98-110
20129251
J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
15956649
Clin Cancer Res. 2006 Nov 1;12(21):6331-6
17085642
Neurosurgery. 2006 Feb;58(1 Suppl):ONS166-9; discussion ONS166-9
16543875
Br J Cancer. 2003 Apr 7;88(7):1004-11
12671695
J Nucl Med. 1999 Feb;40(2):331-8
10025843
Trends Mol Med. 2009 Nov;15(11):519-30
19889578
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
231022
Science. 2008 Sep 26;321(5897):1807-12
18772396
Nature. 2008 Oct 23;455(7216):1129-33
18948956
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Cancer. 2005 Nov 15;104(10):2168-73
16220556
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52
15001257
Cancer Res. 2000 Sep 15;60(18):5143-50
11016641
J Nucl Med. 2006 Mar;47(3):410-8
16513609
FASEB J. 2004 Feb;18(2):338-40
14657001
Cancer Cell. 2007 Jan;11(1):83-95
17222792
Neurosurgery. 2008 May;62(5 Suppl):A11-7; discussion A17-8
18580775
Cancer Cell. 2002 Apr;1(3):269-77
12086863
Neurosurgery. 1999 Apr;44(4):795-804; discussion 804-6
10201305
J Nucl Med. 2005 Jun;46(6):945-52
15937304
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1246-53
17967314
Cancer Cell. 2004 Nov;6(5):507-16
15542434
Radiology. 1993 Jan;186(1):45-53
8380108
J Neurosurg. 2006 Aug;105(2):271-8
17219833
Cancer Cell. 2009 Mar 3;15(3):220-31
19249680
Invest New Drugs. 2005 Aug;23(4):357-61
16012795
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
20399036
Nature. 2009 Dec 10;462(7274):739-44
19935646
Clin Cancer Res. 2006 May 1;12(9):2716-29
16675563
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94
18565358
J Clin Oncol. 2002 Mar 15;20(6):1635-42
11896114
J Immunol. 1992 May 15;148(10):3140-6
1315829
Int J Cancer. 1999 Feb 19;84(1):10-8
9988225
Nat Rev Cancer. 2008 Aug;8(8):604-17
18497750
Neuro Oncol. 2003 Apr;5(2):79-88
12672279
J Neurooncol. 2010 Jan;96(2):219-30
19562254
Ann Oncol. 2009 Sep;20(9):1596-1603
19491283
Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
18496181
Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61
19499221
Med Dosim. 2008 Winter;33(4):268-74
18973853
J Clin Oncol. 2005 Aug 10;23(23):5294-304
15998902
Clin Neurosurg. 2008;55:20-6
19248665
J Clin Oncol. 2009 Apr 20;27(12):2052-8
19307505
Cancer Res. 2009 Jul 1;69(13):5296-300
19549889
Cancer Res. 1990 Oct 15;50(20):6683-8
2208133
J Neurosurg. 1999 Aug;91(2):251-60
10433313
Neurology. 2009 Apr 7;72(14):1217-22
19349600
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2858-62
2565039
Acta Oncol. 2009;48(1):52-8
19031176
Nature. 2006 Dec 21;444(7122):1032-7
17183313
Nat Rev Neurosci. 2007 Aug;8(8):610-22
17643088
Clin Cancer Res. 2006 Aug 15;12(16):4899-907
16914578
J Neurooncol. 2009 Feb;91(3):329-36
18953493
Med Dosim. 2003 Winter;28(4):261-5
14684191
N Engl J Med. 2008 Jul 31;359(5):492-507
18669428
Small. 2008 Nov;4(11):1925-9
18752211
Lancet. 2002 Mar 23;359(9311):1011-8
11937180
J Clin Oncol. 2006 Aug 1;24(22):3651-6
16877733
Neurol Clin. 2007 Nov;25(4):1005-33, ix
17964024
J Neurosurg. 2009 Jan;110(1):173-80
18834263
J Clin Oncol. 1999 Sep;17(9):2762-71
10561351
J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9
8230263
Science. 2009 Apr 10;324(5924):261-5
19359588
Nature. 2008 Oct 23;455(7216):1061-8
18772890
Neurosurgery. 2008 Feb;62 Suppl 2:575-97; discussion 597-8
18596446
Neurology. 2008 Mar 4;70(10):779-87
18316689
Acta Neurochir (Wien). 2003 Jan;145(1):5-10
12545256
J Proteome Res. 2007 Feb;6(2):559-70
17269713
J Clin Oncol. 2009 Mar 10;27(8):1268-74
19204207
Neurology. 2006 Apr 25;66(8):1258-60
16636248
J Clin Oncol. 2007 Jun 20;25(18):2601-6
17577040
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Am J Pathol. 2003 Apr;162(4):1083-93
12651601
Lancet. 1995 Apr 22;345(8956):1008-12
7723496
Science. 1999 Jun 18;284(5422):1994-8
10373119
Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1793-800
3531110
Oncogene. 2004 Jun 3;23(26):4594-602
15077177
Br J Cancer. 2000 Sep;83(5):588-93
10944597
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10842-7
9724792
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8
18006772
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60
15465203
Semin Radiat Oncol. 2009 Jul;19(3):171-8
19464632
Clin Cancer Res. 2009 Sep 1;15(17):5297-302
19706811
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):124-8
9711744
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55
16111571
Lab Invest. 2004 Apr;84(4):397-405
14990981
Int J Cancer. 1994 Jul 15;58(2):240-7
7517920
Neuro Oncol. 2010 Feb;12(2):116-21
20150378